At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NVS Novartis AG
Post-Market Trading 05-13 17:50:12 EDT
102.26
+0.16
+0.16%
盘后102.35
+0.09+0.09%
17:12 EDT
High102.69
Low102.15
Vol1.10M
Open102.44
D1 Closing102.10
Amplitude0.53%
Mkt Cap208.65B
Tradable Cap199.95B
Total Shares2.04B
T/O112.79M
T/O Rate0.06%
Tradable Shares1.96B
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Voyager Therapeutics up 8% following quarterly beats
Top Midday Stories: Novo Nordisk, Linde Shares Fall Post-Earnings; Peloton Shares Plummet After Announcing Job Cuts, CEO Change; Exxon-Pioneer Deal Gets FTC Approval With One Caveat
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.